Armin Walter Novak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Armin Walter Novak has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Marc Schneider
Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, Campus C4 1, 66123 Saarbrücken, Germany
2 shared publications - Agnes-Valencia Weiss
Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology Saarland University Saarbrücken Germany
1 shared publication - Alexander Horn
Institute of Organic Chemistry Saarland University P.O. Box 151150 66041 Saarbrücken Germany
1 shared publication Anja Himmelstein
Freie Universität Berlin, Institute of Pharmacy, Biopharmaceuticals, Berlin, Germany
1 shared publication- Camilla Passi
Department of Pharmacy, Pharmaceutical Materials and Processing, Saarland University, Campus C4.1, 66123 Saarbruecken, Germany
1 shared publication Christoph André Nilius
University of Applied Sciences Kaiserslautern, Zweibrücken, Germany
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in npj Viruses
- Vol. 4 (1) , 52
Towards anti-influenza nasal sprays: infection models and opportunities to reduce animal testing
The nasal mucosa is an important site of influenza virus entry and early replication, yet approved antivirals are not designed for nasal delivery. This Review summarizes antiviral strategies suitable for nasal administration and evaluates animal and human-relevant models for their development. We discuss route-specific formulation and regulatory requirements and propose a translational framework integrating in vitro, ex vivo and microphysiological systems with targeted in vivo studies to reduce animal use.
- 2 November 2026
- Published by Springer Nature in npj Viruses
- Vol. 4 (1) , 52
Open AccessTowards anti-influenza nasal sprays: infection models and opportunities to reduce animal testing
The nasal mucosa is an important site of influenza virus entry and early replication, yet approved antivirals are not designed for nasal delivery. This Review summarizes antiviral strategies suitable for nasal administration and evaluates animal and human-relevant models for their development. We discuss route-specific formulation and regulatory requirements and propose a translational framework integrating in vitro, ex vivo and microphysiological systems with targeted in vivo studies to reduce animal use.
- Open Access
- 29 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 419
The Role of Biofunctional Polymers in Polymer–Drug Conjugates: From Passive Carriers to Therapeutically Active Platforms
Polymer–drug conjugates (PDCs) represent an advanced drug delivery strategy designed to address critical limitations of conventional therapeutics, including poor water solubility, rapid systemic clearance, and off-target toxicity. By covalently linking therapeutic agents to polymeric carriers through rationally designed linkers, PDCs enable improved pharmacokinetic profiles, enhanced stability, and controlled drug release. This review provides a comprehensive overview of the key design principles governing PDC systems, with a particular focus on the role of biofunctional polymers. Essential parameters for polymer selection, including biocompatibility, biodegradability, molecular weight, and functional group availability, are discussed in relation to their influence on drug loading, release kinetics, and biological performance. In addition, both natural and synthetic polymers are evaluated for their ability to improve solubility, modulate biodistribution, and reduce systemic toxicity. An overview of stimuli-responsive PDCs is provided, including pH-, redox-, and temperature-sensitive systems, which enable site-specific and spatiotemporally controlled drug release in response to pathological microenvironments. We emphasize the special role of bioactive polymers such as poly-lysine, hyaluronic acid, chitosan, and gelatin for their intrinsic biological activity, including receptor-mediated targeting, antimicrobial activity, and synergistic therapeutic effects. These properties support the development of dual-active conjugates with enhanced specificity and efficacy. Overall, this review underscores the transition of polymers from passive carriers to active therapeutic components and outlines current challenges and future perspectives for the clinical translation of next-generation PDCs.
- 29 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 419
Open AccessThe Role of Biofunctional Polymers in Polymer–Drug Conjugates: From Passive Carriers to Therapeutically Active Platforms
Polymer–drug conjugates (PDCs) represent an advanced drug delivery strategy designed to address critical limitations of conventional therapeutics, including poor water solubility, rapid systemic clearance, and off-target toxicity. By covalently linking therapeutic agents to polymeric carriers through rationally designed linkers, PDCs enable improved pharmacokinetic profiles, enhanced stability, and controlled drug release. This review provides a comprehensive overview of the key design principles governing PDC systems, with a particular focus on the role of biofunctional polymers. Essential parameters for polymer selection, including biocompatibility, biodegradability, molecular weight, and functional group availability, are discussed in relation to their influence on drug loading, release kinetics, and biological performance. In addition, both natural and synthetic polymers are evaluated for their ability to improve solubility, modulate biodistribution, and reduce systemic toxicity. An overview of stimuli-responsive PDCs is provided, including pH-, redox-, and temperature-sensitive systems, which enable site-specific and spatiotemporally controlled drug release in response to pathological microenvironments. We emphasize the special role of bioactive polymers such as poly-lysine, hyaluronic acid, chitosan, and gelatin for their intrinsic biological activity, including receptor-mediated targeting, antimicrobial activity, and synergistic therapeutic effects. These properties support the development of dual-active conjugates with enhanced specificity and efficacy. Overall, this review underscores the transition of polymers from passive carriers to active therapeutic components and outlines current challenges and future perspectives for the clinical translation of next-generation PDCs.
- Open Access
- 20 February 2025
- Published by Wiley in Macromolecular Chemistry and Physics
- Vol. 226 (10)
Comparative Analysis of Two Elastic Types of Surface‐Crosslinked Gelatin Nanoparticles as Suitable Systems for Macromolecular Drug Delivery
With a steadily rising number of novel biopharmaceuticals in development, the demand for applicable delivery systems for macromolecular drugs persists. Polymeric nanoparticles, consisting of the natural product gelatin, present beneficial attributes for this application. To stabilize those nanoparticles without interfering with encapsulated macromolecules, surface‐crosslinked gelatin particles are developed and thoroughly characterized for their physicochemical and mechanical properties. With only limited data available for the latter, investigating the elastic properties can offer a more comprehensive understanding of the crosslinking processes involved and of the gelatin particles’ potential applications. In this study, protocols for surface‐crosslinked gelatin particles type A (GNP‐A) and B (GNP‐B) are described. Significant differences between the two types of gelatin are reported regarding their physicochemical and mechanical properties. GNP‐A consists of a lower crosslinking degree, leading to pronounced swelling in aqueous environments and softer nanoparticles. They possess contrary properties compared to the more extensively crosslinked and stiffer GNP‐B. However, this doesn't affect encapsulation efficiency, allowing to develop nanoparticulate systems suitable for various applications by adjusting the particle properties while maintaining the same drug load. These findings provide a deeper understanding of polymeric gelatin particles and reveal the importance of investigating the mechanical properties of drug delivery systems during pharmaceutical development.
- 20 February 2025
- Published by Wiley in Macromolecular Chemistry and Physics
- Vol. 226 (10)
Open AccessComparative Analysis of Two Elastic Types of Surface‐Crosslinked Gelatin Nanoparticles as Suitable Systems for Macromolecular Drug Delivery
With a steadily rising number of novel biopharmaceuticals in development, the demand for applicable delivery systems for macromolecular drugs persists. Polymeric nanoparticles, consisting of the natural product gelatin, present beneficial attributes for this application. To stabilize those nanoparticles without interfering with encapsulated macromolecules, surface‐crosslinked gelatin particles are developed and thoroughly characterized for their physicochemical and mechanical properties. With only limited data available for the latter, investigating the elastic properties can offer a more comprehensive understanding of the crosslinking processes involved and of the gelatin particles’ potential applications. In this study, protocols for surface‐crosslinked gelatin particles type A (GNP‐A) and B (GNP‐B) are described. Significant differences between the two types of gelatin are reported regarding their physicochemical and mechanical properties. GNP‐A consists of a lower crosslinking degree, leading to pronounced swelling in aqueous environments and softer nanoparticles. They possess contrary properties compared to the more extensively crosslinked and stiffer GNP‐B. However, this doesn't affect encapsulation efficiency, allowing to develop nanoparticulate systems suitable for various applications by adjusting the particle properties while maintaining the same drug load. These findings provide a deeper understanding of polymeric gelatin particles and reveal the importance of investigating the mechanical properties of drug delivery systems during pharmaceutical development.